Avid Bioservices Inc (NASDAQ:CDMO) Director Mark R. Bamforth purchased 50,000 shares of the company’s stock in a transaction on Thursday, February 15th. The stock was acquired at an average cost of $2.25 per share, for a total transaction of $112,500.00. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink.
Shares of Avid Bioservices Inc (NASDAQ:CDMO) opened at $2.53 on Wednesday. Avid Bioservices Inc has a 1-year low of $2.24 and a 1-year high of $5.78.
Avid Bioservices (NASDAQ:CDMO) last released its quarterly earnings data on Monday, December 11th. The biopharmaceutical company reported ($0.27) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.12) by ($0.15). The firm had revenue of $12.78 million for the quarter, compared to the consensus estimate of $13.54 million. Avid Bioservices had a negative net margin of 39.23% and a negative return on equity of 52.55%. equities research analysts forecast that Avid Bioservices Inc will post -0.57 EPS for the current year.
Several equities analysts have issued reports on the company. Noble Financial reissued a “buy” rating on shares of Avid Bioservices in a research note on Friday, January 5th. Zacks Investment Research raised Avid Bioservices from a “sell” rating to a “hold” rating in a research note on Saturday, November 18th. Finally, ValuEngine lowered Avid Bioservices from a “hold” rating to a “sell” rating in a research note on Friday, December 1st.
TRADEMARK VIOLATION NOTICE: This article was originally posted by Stock Observer and is the property of of Stock Observer. If you are reading this article on another domain, it was stolen and republished in violation of United States and international copyright and trademark law. The original version of this article can be read at https://www.thestockobserver.com/2018/02/21/avid-bioservices-inc-cdmo-director-mark-r-bamforth-acquires-50000-shares.html.
About Avid Bioservices
Avid Bioservices, Inc, formerly Peregrine Pharmaceuticals, Inc, is a biopharmaceutical company. The Company is engaged in providing contract manufacturing services for third party customers on a fee-for-service basis while also supporting its internal drug development efforts. The Company delivers pharmaceutical products through its contract manufacturing business and through licensing its development-stage immunotherapy products.
Receive News & Ratings for Avid Bioservices Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Avid Bioservices and related companies with MarketBeat.com's FREE daily email newsletter.